GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...

GE HealthCare has dosed the first patient in a Phase 2/3 trial of a manganese-based MRI contrast agent and secured FDA clearance for three next-generation SIGNA MRI systems. The contrast agent aims to ...

MONTREAL, April 17, 2026 /CNW/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY (R) injection (gadopiclenol), a macrocyclic gadolinium-based ...

A magnetic resonance imaging (MRI) scan is an important tool to help doctors see what’s happening inside your body. But new, preliminary research suggests that a contrast agent used in some MRIs could ...

PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...

T SWI enhances brain imaging clarity over 3.0 T in healthy adults. Read more on improved neuroanatomical visualisation.